Target Name: CCR3
NCBI ID: G1232
Review Report on CCR3 Target / Biomarker Content of Review Report on CCR3 Target / Biomarker
CCR3
Other Name(s): OTTHUMP00000209745 | C-C chemokine receptor type 3 (isoform X2) | C C CKR3 | CC chemokine receptor 3 | C-C chemokine receptor type 3, transcript variant X3 | CCR-3 | CMKBR3 | C-C motif chemokine receptor 3 | chemokine (C-C motif) receptor 3 | eosinophil eotaxin receptor | C-C chemokine receptor type 3 | CKR 3 | eosinophil CC chemokine receptor 3 | CCR3 variant X3 | b-chemokine receptor | CCR3_HUMAN | C-C motif chemokine receptor 3, transcript variant 1 | C-C chemokine receptor type 3 (isoform 1) | Eosinophil CC chemokine receptor 3 | b-Chemokine receptor | C-C CKR-3 | Chemokine (C-C motif) receptor 3 | CKR3 | CC-CKR-3 | B-chemokine receptor | CCR3 variant 1 | CD193 | Eosinophil eotaxin receptor | MGC102841

CCR3: A Potential Cancer Target and Biomarker

CCR3 (Complement Component 3) is a protein that is expressed in various tissues throughout the body. It is a key component of the complement system, which is a group of proteins that work together to help the immune system fight off infections. CCR3 is a 21-kDa protein that consists of 215 amino acids. It is characterized by the presence of a N-terminal extracellular domain, a T-terminal domain, and a C-terminal terminal domain.

CCR3 is involved in the regulation of cellular processes such as cell adhesion, migration, and invasion. It is also involved in the production of granulocyte-derived neurotrophic factor (GDNF), which is a protein that supports the survival and proliferation of neural cells.

CCR3 is a potential drug target because of its involvement in cellular processes that are important for the development and progression of cancer. It is also a good candidate for targeting because of its unique structure, which allows for the development of small molecules that can interact with it in a targeted manner.

One of the challenges in targeting CCR3 is its high expression level. CCR3 is expressed in most tissues and is highly upregulated in many types of cancer. This makes it difficult to inhibit its activity with small molecules, as the compound needed to inhibit CCR3 may also be harmful to the cell.

Another challenge is the difficulty in identifying the specific CCR3 isoform that is involved in cancer progression. CCR3 is expressed in different isoforms, which are different forms of the protein that are produced by alternative splicing. It is not clear which isoform is involved in cancer progression. , which could limit the effectiveness of any potential drug that targets CCR3.

However, researchers are actively working to overcome these challenges and develop CCR3-targeted drugs. Researchers have identified several small molecules that can interact with CCR3 and are currently in the process of testing them for their potential as cancer therapies.

One of the most promising small molecules is a compound called TAT-424. TAT-424 is a peptide that consists of the amino acids Asp-214, Asn-215, Glu-216, Lys-217, Asp-218, Asn-219 , Glu-220, Lys-221, Asp-222, and Lys-223. TAT-424 is able to interact with CCR3 and has been shown to inhibit its activity in cell experiments.

Another small molecule that is being tested for its potential as a CCR3 inhibitor is called IPT-2. IPT-2 is a peptide that consists of the amino acids Asp-195, Asn-196, Glu-197, Lys-198, Asp- 200, Asn-201, Glu-202, Lys-203, Asp-204, and Lys-205. IPT-2 has also been shown to interact with CCR3 and has the potential to be a CCR3 inhibitor.

CCR3 is also a potential biomarker for cancer. Its expression is often increased in cancer cells, which makes it a potential indicator of the disease. This makes CCR3 an attractive target for cancer diagnostics and therapies.

In conclusion, CCR3 is a protein that is involved in the regulation of cellular processes that are important for the development and progression of cancer. It is a potential drug target and biomarker, and researchers are actively working to develop small molecules that can inhibit its activity . Further studies are needed to determine the most effective and safe small molecules that can be used to target CCR3.

Protein Name: C-C Motif Chemokine Receptor 3

Functions: Receptor for C-C type chemokine. Binds and responds to a variety of chemokines, including CCL11, CCL26, CCL7, CCL13, RANTES(CCL5) and CCL15 (PubMed:7622448, PubMed:8642344, PubMed:8676064). Subsequently transduces a signal by increasing the intracellular calcium ions level (PubMed:8676064). In addition acts as a possible functional receptor for NARS1 (PubMed:30171954)

The "CCR3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCR3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58